Unknown

Dataset Information

0

Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening.


ABSTRACT: Lowering total tau levels is an attractive therapeutic strategy for Alzheimer's disease and other tauopathies. High-throughput screening in neurons derived from human induced pluripotent stem cells (iPSCs) is a powerful tool to identify tau-targeted therapeutics. However, such screens have been hampered by heterogeneous neuronal production, high cost and low yield, and multi-step differentiation procedures. We engineered an isogenic iPSC line that harbors an inducible neurogenin 2 transgene, a transcription factor that rapidly converts iPSCs to neurons, integrated at the AAVS1 locus. Using a simplified two-step protocol, we differentiated these iPSCs into cortical glutamatergic neurons with minimal well-to-well variability. We developed a robust high-content screening assay to identify tau-lowering compounds in LOPAC and identified adrenergic receptors agonists as a class of compounds that reduce endogenous human tau. These techniques enable the use of human neurons for high-throughput screening of drugs to treat neurodegenerative disease.

SUBMITTER: Wang C 

PROVIDER: S-EPMC5639430 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening.

Wang Chao C   Ward Michael E ME   Chen Robert R   Liu Kai K   Tracy Tara E TE   Chen Xu X   Xie Min M   Sohn Peter Dongmin PD   Ludwig Connor C   Meyer-Franke Anke A   Karch Celeste M CM   Ding Sheng S   Gan Li L  

Stem cell reports 20170928 4


Lowering total tau levels is an attractive therapeutic strategy for Alzheimer's disease and other tauopathies. High-throughput screening in neurons derived from human induced pluripotent stem cells (iPSCs) is a powerful tool to identify tau-targeted therapeutics. However, such screens have been hampered by heterogeneous neuronal production, high cost and low yield, and multi-step differentiation procedures. We engineered an isogenic iPSC line that harbors an inducible neurogenin 2 transgene, a t  ...[more]

Similar Datasets

| S-EPMC4697850 | biostudies-literature
| S-EPMC10119332 | biostudies-literature
| S-EPMC8143197 | biostudies-literature
| S-EPMC9386098 | biostudies-literature
2019-10-31 | MSV000084521 | MassIVE
| S-EPMC2944895 | biostudies-literature
| S-EPMC8608971 | biostudies-literature
| S-EPMC9103414 | biostudies-literature
| S-EPMC7370446 | biostudies-literature
| S-EPMC4049307 | biostudies-literature